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viral RNAi is activated by processing viral
double-stranded RNA (dsRNA) replication
intermediates into virus-derived small
interfering RNAs (vsiRNAs). Typically of a
discrete length of 22 nt, vsiRNAs form
perfect duplexes, with 2 nt 30 overhangs
diagnostic of the Dicer-like RNase III
activities that generate them across
kingdoms. vsiRNAs are loaded into and
guide Argonaute (AGO) nucleases in order
to subsequently suppress virus accumu-
lation (Ding and Voinnet, 2007). Attesting
to the importance of antiviral RNAi, the
virulence of plant and invertebrate viruses
requires production of virus-encoded
suppressors of RNAi (VSRs) that become
dispensable for infection in RNAi-defec-
tive hosts (Ding and Voinnet, 2007).
Comparatively, antiviral RNAi in mam-
mals remains a hotly debated issue: vi-
rus-derived small RNAs (vsRNAs, unlike
the vsiRNAs evoked above) isolated
in numerous infections of mammalian
differentiated cell lines do not conform
to the definition of siRNAs; their random
size-distribution and strong strand bias
usually reflect the unspecific degradation
of a single, abundant viral RNA strand
(Parameswaran et al., 2010). Perhaps
unsurprisingly, therefore, the replication
of many viruses is unchanged in differen-
tiated cells in which Dicer function is
genetically disabled (Bogerd et al. 2014).
This overall uncertainty has led to a hy-
pothesis that the interferon response,
which also detects viral dsRNA, may
prevent dsRNA recognition by RNAi in
mammals.
The above premises have led our
groups to explore antiviral RNAi in
pluripotent mouse embryonic stem cells
(ESCs) that lack a potent interferon
response (Maillard et al., 2013, Wang
et al., 2014). Bona fide siRNAs weresignificantly enriched in the 50 terminal
genomic RNA regions of two distinct
viruses, but, importantly, their accu-
mulation was strongly attenuated upon
ESC differentiation, leading Maillard
et al. (2013) to suggest that multipotency
might constitute another, and perhaps
major, prerequisite tomammalian antiviral
RNAi. Focusing on one of these viruses,
Li et al. (2013) showed that highly abun-
dant vsiRNAs, identical to those detected
in ESCs, accumulated in systemically in-
fected suckling mice, but only if a VSR
inhibiting mammalian Dicer was disabled
from the viral genome. vsiRNA accumula-
tion in vivo correlated with the clearance
of the VSR-deficient virus, suggesting
that antiviral RNAi operates in vivo (Li
et al., 2013). Importantly, replication of
the VSR-deficient virus was partially
restored in mouse ESCs lacking an RNAi
response (Maillard et al., 2013). Rescue
of VSR-deficient viruses in RNAi-deficient
hosts has been the defining experiment
in all model organisms to conclude the
antiviral nature of RNAi (Ding and Voinnet
2007), and so it was concluded that
RNAi is indeed antiviral, at least in
mouse ESCs. Mammalian antiviral RNAi
studies are also complicated by the fact
that several viral genomes interact
directly with host-encoded, Dicer-depen-
dent microRNAs (miRNAs). Specific host
miRNAs may either enhance or inhibit
virus infection, as shown for hepatitis
C virus in hepatocytes and vesicu-
lar stomatitis virus (VSV) in murine macro-
phages, respectively (Jopling et al., 2005;
Otsuka et al., 2007).
In a recent manuscript focusing on
VSV, Backes et al. (2014) concluded that
the in vitro and in vivo mammalian re-
sponses to infection are independent
of silencing by either vsiRNAs or host-
encodedmiRNAs and that, consequently,Cell Reports 9, 795–797,RNAi therapies, including their virus-
based formulations, should now be con-
sidered safe to mammals and humans.
However, our analysis shows that these
conclusions are not supported by the
experiments presented for the following
reasons.
Virus Choice
As shown previously (Parameswaran
et al., 2010), the authors found that
vsRNAs from three distinct RNA viruses
do not display any size preference indica-
tive of RNAi activity in differentiated
mouse cells. By contrast, they claim that
vsRNAs from VSV (a negative-strand
RNA virus) in infected mouse embryonic
fibroblasts (MEFs) are dominantly 22 nt
in length and enriched at the ends of the
genome, features they deem ‘‘reminis-
cent of the RNAi-like activity recently
described in mammalian cells’’ (Maillard
et al., 2013; Li et al., 2013). However, our
analysis of the sequencing reads shows
that the authors presented the size distri-
bution only for the low-abundance VSV
positive strand, whereas the genomic dis-
tribution for both positive- and negative-
strand vsRNAs was collapsed onto a
virtual VSV negative genome. When reads
from both viral strands are analyzed and
their polarity is considered—the norm
in all studies conducted thus far—the
sequenced vsRNAs display a random
size-distribution and strong negative-
strand bias (Figures 1A–1D), indicating
that they are RNA degradation products
not different from those of the other three
viruses tested by the authors or indeed
from other vsRNAs previously character-
ized in mammalian differentiated cells
(Parameswaran et al., 2010). Therefore,
the assertion that VSV-derived vsRNAs
are reminiscent of mammalian vsiRNAs
is misleading, and, more importantly, theNovember 6, 2014 ª2014 The Authors 795
Figure 1. VSV-Derived Small RNAs Are Mere Degradation Fragments
(A) Our analysis of VSV-derived reads from both viral strands reveals the absence of any particular length bias. Note also that reads from the nonanalyzed strand
are more abundant by at least one order of magnitude.
(B) The size distribution of VSV-derived reads shown in (A) is now not distinguishable from that of the other viruses tested by the authors (panel extracted from
Backes et al., 2014).
(C) The VSV reads presented in Backes et al. (2014) are somehow collapsed onto a virtual negative viral genomic RNA and thus intrinsically uninformative about
the respective contribution of each viral strand to vsRNA production.
(D) A stranded genomic distribution of VSV reads upon our reanalysis of the author’s data reveals a strong read bias for the negative strand, which is much more
abundant in infected cells owing to VSV replication. Note that the genomic distribution of VSV reads remains unchanged if all read sizes (18–25 nt) are compared
to the 22 nt-only reads. This, along with the strong strand bias, shows that VSV-derived vsRNAs are simply degradation products.
(E) Comparison of the respective accumulation of miR-93, miR-24, and miR-378 in noninfected MEFs and RAW cells. Both data sets were generated via Illumina
deep sequencing of comparable depth and normalized as reads per million. The RAW cell data are from Zheng et al. (2012). The MEFs data are from the Voinnet
laboratory.authors’ choice of VSV to further investi-
gate antiviral RNAi unjustified (additional
concerns are discussed in brief in the
Supplemental Information).
Test of Silencing Suppression
by VSV
Backes et al. (2014) then argue they test
whether VSV encodes an inhibitor of
silencing to ensure that small RNAs
can target VSV in the context of their
mammalian systems. Their observations796 Cell Reports 9, 795–797, November 6, 20that recombinant VSV can (1) be targeted
by an endogenous miRNA and (2) pro-
duce an artificial miRNA were used to
conclude that ‘‘VSV does not encode
an inhibitor of small RNA silencing.’’ How-
ever, the authors ignore the results of
identical experiments conducted previ-
ously with plant viruses encoding VSRs
targeting both the miRNA and siRNA
pathways: these viruses can produce
functional miRNAs engineered in their
genome and are also efficiently targeted14 ª2014 The Authorsby endogenous miRNAs despite expres-
sion of potent VSRs (Simo´n-Mateo and
Garcı´a, 2006; Tang et al., 2013). Virus-
induced gene silencing of host mRNAs
is also routinely achieved with VSR-
encoding viruses and hairpin-derived
silencing immunizes transgenic crops
against aggressive diseases from VSR-
proficient viruses (Simo´n-Mateo and Gar-
cı´a, 2006). Therefore, the rationale behind
those experiments is flawed, and the
results presented cannot be used to
conclude that VSV does not encode a
VSR or that an engineered expression of
a heterologous VSR must enhance VSV
replication.
In Vitro Effects of VP55 on
VSV Levels
The authors previously identified a
vaccinia virus protein, VP55, which spe-
cifically degrades miRNAs and siRNAs
but only if they are loaded into an
AGO complex and not protected by
20-O-methylation. Here, Backes et al.
(2014) engineer VSV variants in order to
express VP55 (VSV-VP55) or a control
insert (VSV-Ctrl) and compare their accu-
mulation in order to assess the potential
contribution of antiviral RNAi and host
miRNAs to restricting VSV in MEFs. They
observe no change in accumulation
of VSV-VP55 versus VSV-Ctrl, a result
they argue is surprising in light of ‘‘previ-
ous studies [that] have implicated host
miRNAs in the direct silencing of VSV
and RNAi activity in fibroblasts (Li
et al., 2013; Otsuka et al., 2007).’’ This
leads them to make the statement
‘‘these results suggest that small RNAs
do not significantly impact the mam-
malian cellular response to virus infection
in vitro.’’ However, none of the data pre-
sented support these assertions.
First, Otsuka et al. (2007) conclusively
showed that miR-93, miR-24, and, to a
lesser extent, miR-378 have direct anti-
viral effects on VSV in RAW cells, in which
these miRNAs were shown to effectively
accumulate, unlike 21 other miRNAs
with predicted complementarity to the
VSV genome. Thus, the only reported
effects of miRNAs on VSV in vitro impli-
cate three discrete miRNAs found in one
specific cell type. Therefore, to reach
any conclusion, the authors must prove
that at least one of the above-mentioned
miRNAs indeed accumulates in infected
MEFs to levels comparable to those of
infected RAW cells; this is clearly not
the case in noninfected cells (Figure 1E).
Alternatively, they must first conclusively
establish which miRNAs, if any, might
productively restrict VSV in MEFs, as
did Otsuka et al. (2007) with miR-93,
miR-24, and miR-378 in RAW cells.
Besides, given that RAW cells are used
throughout their paper, we question whythe authors did not provide the results of
VSV-VP55 infections in these cells, a legit-
imately expected and decisive experi-
ment. In the absence of these results, their
data are inconclusive.
Second, the only vsRNAs detectable in
VSV-infected MEFs are heterogeneous
RNA degradation products (Figures 1A
and 1B), of which neither the 30-methy-
lation- nor the AGO-loaded status is
known. Given its substrate specificity,
VP55 is highly unlikely to alter the accu-
mulation of these degradation products
that have not been assigned any role in
antiviral defense thus far. Therefore, this
experiment is bound to be inconclu-
sive regarding the potential contribution
of RNAi to the cellular restriction of VSV
in MEFs.
In Vivo Effects of VP55 on
VSV Levels
A final set of experiments showing no dif-
ference in accumulation between VSV-
VP55 and VSV-Ctrl in whole-mouse lungs
leads the authors to suggest ‘‘a functional
antiviral RNAi system is not a physiolog-
ical contributor to mammalian antiviral
defenses.’’ However, this statement is
again unfounded, given that VSV-derived
vsRNAs accumulating in vivo are ‘‘com-
parable to those observed in fibroblasts’’
and thus most likely RNA degradation
products unaffected by VP55. Moreover,
because the identity of the VSV-infected
lung cells and their miRNA repertoire
are undetermined, the experiment is also
inconclusive regarding potential host
miRNA-mediated effects on VSV in vivo.
The authors themselves admit that
‘‘it is difficult to prove the absence of a
biological activity,’’ and indeed the infer-
ence made in their manuscript’s title is
not supported by a definitive experiment.
One emerging aspect apparently not
considered by Backes et al. (2014) is the
likely contextual nature of mammalian
RNAi in vivo: only specific cell niches
and tissues—possibly with features of
adult stem cells—are likely to accumulate
significant levels of bona fide vsiRNAs
(Pare and Sullivan, 2014; Wang et al.,
2014). Identifying these cell niches and
the biochemical features of their associ-
ated vsiRNAs in vivo is therefore an abso-
lute prerequisite if the types of experi-Cell Reports 9, 795–797,ments conducted by Backes et al. (2014)
are to be meaningful. Likewise, the signif-
icance of host miRNA-virus interactions
will only be apparent in cells with well-
established virus-complementary miRNA
repertoires. If mammalian antiviral RNAi
is the attribute of only a fraction of in-
fected cells, does this make those cells
less important? On these premises, the
final conclusion of the authors on the
innocuous nature of mammalian RNAi-
based therapies appears highly prema-
ture and dangerous.SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental
Discussion and can be found with this article online
at http://dx.doi.org/10.1016/j.celrep.2014.10.029.REFERENCES
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